REVIVA PHARMACEUTICALS HOLDINGS INC. - COMMON STO

Reviva to Participate in the BIO International Convention

21 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

15 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

14 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

13 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

09 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

15 апр 2024 07:30:00 Источник Nasdaq GlobeNewswire

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

15 апр 2024 07:05:00 Источник Nasdaq GlobeNewswire

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

28 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

26 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

Reviva to Present at the UBS Virtual CNS Day

11 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

Reviva to Present at the 36th Annual ROTH Conference

07 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

20 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

06 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

25 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

04 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

11 дек 2023 07:00:00 Источник Nasdaq GlobeNewswire

Reviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

30 ноя 2023 15:05:00 Источник Nasdaq GlobeNewswire

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

20 ноя 2023 15:05:00 Источник Nasdaq GlobeNewswire

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

16 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

14 ноя 2023 15:01:00 Источник Nasdaq GlobeNewswire